It was another busy year for Japanese regulators, who approved 38 new drugs in the fiscal year up to the end of this March, roughly maintaining the pace of the the previous 12 months and bringing some important new therapies to patients. New products for oncology and biologics featured heavily, with foreign multinationals dominating the list.
Major Japanese pharma companies will add an estimated net $6.6bn in revenues through products launched over the 10-year period to 2027 to generate a combined total of $69.5bn, although average growth will be low, constrained mainly by pricing factors at home.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.